GH Research (GHRS) Stock Forecast, Price Target & Predictions
GHRS Stock Forecast
GH Research stock forecast is as follows: an average price target of $28.00 (represents a 195.67% upside from GHRS’s last price of $9.47) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
GHRS Price Target
The average price target for GH Research (GHRS) is $28.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $28.00. This represents a potential 195.67% upside from GHRS's last price of $9.47.
GHRS Analyst Ratings
According to 2 Wall Street analysts, GH Research's rating consensus is 'Buy'. The analyst rating breakdown for GHRS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GH Research Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | Sumant Kilkami | Canaccord Genuity | $28.00 | $9.26 | 202.52% | 195.67% |
| May 06, 2024 | Sumant Kilkami | Canaccord Genuity | $31.00 | $11.68 | 165.41% | 227.35% |
The latest GH Research stock forecast, released on Nov 18, 2024 by Sumant Kilkami from Canaccord Genuity, set a price target of $28.00, which represents a 202.52% increase from the stock price at the time of the forecast ($9.26), and a 195.67% increase from GHRS last price ($9.47).
GH Research Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $28.00 | $28.00 | $29.50 |
| Last Closing Price | $9.47 | $9.47 | $9.47 |
| Upside/Downside | 195.67% | 195.67% | 211.51% |
In the current month, the average price target of GH Research stock is $28.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 195.67% increase as opposed to GH Research's last price of $9.47. This month's average price target is down 0.00% compared to last quarter, and down -5.08% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 06, 2024 | Canaccord Genuity | Buy | Buy | Hold |
GH Research's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave GHRS a "Buy" rating, the same as its previous rate.
GH Research Financial Forecast
GH Research Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
GH Research's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GHRS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
GH Research EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict GHRS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than GH Research's previous annual EBITDA (undefined) of $NaN.
GH Research Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-13.27M | $-13.53M | $-13.01M | $-12.23M | $-11.45M | $-12.80M | $-11.45M |
| High Forecast | $-13.27M | $-13.53M | $-13.01M | $-12.23M | $-9.37M | $-12.80M | $-11.45M |
| Low Forecast | $-13.27M | $-13.53M | $-13.01M | $-12.23M | $-13.53M | $-12.80M | $-11.45M |
| Surprise % | - | - | - | - | - | - | - |
GH Research's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GHRS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
GH Research SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
GH Research's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GHRS last annual SG&A of $NaN (undefined).
GH Research EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.23 | $-0.22 | $-0.25 | $-0.22 |
| High Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.23 | $-0.18 | $-0.25 | $-0.22 |
| Low Forecast | $-0.26 | $-0.26 | $-0.25 | $-0.23 | $-0.26 | $-0.25 | $-0.22 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, GH Research's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GHRS previous annual EPS of $NaN (undefined).
GH Research Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.56 | $18.00 | 1053.85% | Buy |
| PEPG | PepGen | $4.13 | $29.50 | 614.29% | Buy |
| HOWL | Werewolf Therapeutics | $1.71 | $12.00 | 601.75% | Buy |
| MOLN | Molecular Partners | $5.83 | $29.00 | 397.43% | Buy |
| RLAY | Relay Therapeutics | $4.89 | $19.40 | 296.73% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.53 | $6.00 | 292.16% | Buy |
| GHRS | GH Research | $9.47 | $28.00 | 195.67% | Buy |
| GPCR | Structure Therapeutics | $31.75 | $92.40 | 191.02% | Buy |
| RZLT | Rezolute | $4.87 | $13.50 | 177.21% | Buy |
| MLYS | Mineralys Therapeutics | $11.40 | $30.00 | 163.16% | Buy |
| STOK | Stoke Therapeutics | $11.88 | $30.60 | 157.58% | Buy |
| ANNX | Annexon | $5.46 | $14.00 | 156.41% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| CGEM | Cullinan Oncology | $13.45 | $31.50 | 134.20% | Buy |
| RCUS | Arcus Biosciences | $14.43 | $33.00 | 128.69% | Buy |
| PHVS | Pharvaris | $20.92 | $39.67 | 89.63% | Buy |
| DSGN | Design Therapeutics | $5.76 | $9.67 | 67.88% | Buy |
| JANX | Janux Therapeutics | $48.12 | $61.20 | 27.18% | Buy |
| IKNA | Ikena Oncology | $1.68 | $1.33 | -20.83% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |